Australia markets closed

Cipla Limited (CIPLA.BO)

BSE - BSE Real-time price. Currency in INR
Add to watchlist
1,424.75+5.20 (+0.37%)
At close: 03:29PM IST
Full screen
Previous close1,419.55
Open1,423.00
Bid1,425.00 x 0
Ask1,425.10 x 0
Day's range1,416.40 - 1,434.20
52-week range897.70 - 1,519.00
Volume32,752
Avg. volume31,852
Market cap1.15T
Beta (5Y monthly)0.37
PE ratio (TTM)31.07
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield8.50 (0.60%)
Ex-dividend date21 July 2023
1y target estN/A
  • Reuters

    India pharma companies develop versions of Wegovy to get in on weight-loss windfall

    Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.